Quetiapine (50 mg/day-100mg/day)
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Bowel Disorders
Conditions
Functional Bowel Disorders
Trial Timeline
Feb 1, 2008 → May 1, 2012
NCT ID
NCT00617396About Quetiapine (50 mg/day-100mg/day)
Quetiapine (50 mg/day-100mg/day) is a pre-clinical stage product being developed by AstraZeneca for Functional Bowel Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00617396. Target conditions include Functional Bowel Disorders.
What happened to similar drugs?
0 of 6 similar drugs in Functional Bowel Disorders were approved
Approved (0) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00617396 | Pre-clinical | Completed |
Competing Products
20 competing products in Functional Bowel Disorders